ClinicalTrials.gg
CompletedNCT03476746Updated Feb 24, 2025

Dermatopharmacokinetic Trial of LEO 90100 Foam

A Phase 1 interventional study of LEO 90100 foam and Dovobet® ointment in Healthy, sponsored by LEO Pharma. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

This is a phase 1, single centre trial in Japanese healthy male subjects comparing the amount of active ingredients of LEO 90100 foam and Dovobet® ointment in the stratum corneum.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male subjects, aged 20 to 40 years inclusive

Exclusion criteria

Exclusion Criteria:

  • outside the range 18-25 kg/m²
  • Use of any medication (systemic or topical) within 2 weeks of Day 1.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    LEO 90100 foam

    LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g). Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total). Pivotal part: To be decided based on the result of the pilot part

    Drug: LEO 90100 foam

  • Active comparator
    Dovobet® ointment

    Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total). Pivotal part: To be decided based on the result of the pilot part

    Drug: Dovobet® ointment

Interventions

  • DrugLEO 90100Studies of LEO 90100LEO 90100 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A foam formulation of the active comparator Dovobet® ointment

  • DrugDovobet® ointment

    Ointment formulation containing same active ingredients as LEO 90100 foam

06

What researchers measure

Primary outcomes

  1. The amount of each of the 2 active ingredients, calcipotriol and betamethasone dipropionate, in the stratum corneum obtained by means of tape stripping after application of LEO 90100 foam and Dovobet® ointment.

    Amount (nanogram) of calcipotriol and betamethasone dipropionate in the stratum corneum will be compared between the two formulations by selected time points using an ANOVA model with treatment/formulation as systematic effect.

    Time frame: 2, 4, 6, 8, 12 and 24 hr after drug application.

Secondary outcomes

  1. Safety data - number of adverse events

    Number of adverse events

    Time frame: up to 15 Days after drug application

07

Study locations

1 site
  • Investigational site
    Fukuoka, 812-0025, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jul 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2018
First posted
Mar 26, 2018
StartActual
Mar 20, 2018
Primary completionActual
Jul 1, 2018
CompletionActual
Jul 1, 2018
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03476746
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Mar 20, 2018
Primary completion
Jul 1, 2018
Completion
Jul 1, 2018
Last update
Feb 24, 2025

Study contacts

Study Director
study director · LEO Pharma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LEO 90100

Start the discussion